Although the increase in the number of HER-2 gene copies had a significant positive impact on the pCR rate, there was no significant difference between HA tumours (>10 HER-2 gene copies per nuclei) and LA tumours (6–10 HER-2 gene copies per nuclei) for either RFS or OS after a median follow-up of 46 months. This evidence concerns the gene ERBB2 and neoplasm.